Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of 68Ga-DFC413 and 68Ga-NNS309 in Solid Tumors
NCT07630961Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 2
01
Overview
Phase 1, open-label trial of 68Ga-DFC413 in pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer and 3 more (2 arms), sponsored by Novartis. Primary endpoints: Standard Uptake Value up to 240 minutes, Standard Uptake Value ratio up to 240 minutes and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
68Ga-DFC413
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)non-small cell lung cancer (NSCLC)breast cancertriple-negative breast cancer (TNBC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07630961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07630961.